November 2, 2023 10:47 AM EDT
News Briefing

Pro­tag­o­nist's $50M mile­stone; Swiss biotech rais­es $27M; Kymera halts a PhI

Jaimy Lee

Deputy Editor

Plus, news from CEPI and Pro­JenX:

Pro­tag­o­nist Ther­a­peu­tics records a $50M mile­stone: The com­pa­ny said Wednes­day that it’s get­ting a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Gar­dasil de­mand in Chi­na sinks, and Mer­ck ex­pects the same next quar­ter

‘Im­i­ta­tion is best form of flat­tery’: Re­gen­eron CEO com­ments on Am­gen’s Eylea biosim­i­lar

UCB's an­ti-tau Alzheimer's pro­gram fails Phase 2 pri­ma­ry end­point, but high­lights pos­i­tive sec­on­daries

Am­gen makes pipeline cuts, but obe­si­ty plans re­main the fo­cus

Ab­b­Vie adds to T cell en­gager mo­men­tum, with EvolveIm­mune pact start­ing at $65M

Q&A: Jade CEO talks about re­verse merg­er and IgAN drugs

A service from the Financial Times